NCT03837743View on ClinicalTrials.gov

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

November 11, 2019

Study Completion Date

May 20, 2020

Conditions
Plaque Psoriasis
Interventions
DRUG

DUR-928 Topical Solution

Topical solution containing active drug

DRUG

Vehicle Topical Solution

Topical solution containing no active drug

Trial Locations (5)

33162

Site 04, Miami

33609

Site 05, Tampa

46168

Site 02, Plainfield

92123

Site 01, San Diego

99202

Site 03, Spokane

Sponsors

Lead Sponsor

Durect
All Listed Sponsors
collaborator

Therapeutics, Inc.

INDUSTRY

lead

Durect

INDUSTRY